Department of Health and Human Services
Public Health Service
Waterview Corporate Ctr
November 29, 2005
VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED
984 Route 9 S #11
Parlin, NJ 08859
Ref. No. NWJ-06-07
Dear Mr Jordan:
The Food and Drug Administration (FDA) has reviewed your website at the Internet address www.neugenisis.com and has concluded that claims in the labeling for your product Lingoji cause the product to be a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)(B)]. You can find the Act and FDA's regulations through links on FDA's Internet homepage at www.fda.gov.
Under the Act, articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man are drugs [Section 201(g)(1)(B) of the Act, 21 USC 321(g)(1)(B)]. Your website claims that your product is useful in the prevention and treatment of avian flu and other forms of influenza.
The Internet labeling of your product bears the foIIowing claims:
- (Under page heading "Lingoji™; from Neulife Laboratories") "As seen on CNN, … PrimeTime, etc. Protect yourself from the Avian Flu. The Nation may be unprepared, according to certain experts, but you can improve your defenses."
- (Testimonial) "I have bad a history of bad flu seasons's [sic] … the past couple of years. I started taking Liugoji. … For the first time in 5 years, I have enjoyed a full season without sickness."
- (Testimonial) "The talk and treat of these epidemis, flu's [sic], etc lead me to my Doctor. He actually recommended Lingoji … I am looking to the flu season WITHOUT the flu."
These claims cause your product to be a drug, as defined in section 201(g)(1)(B) of the Act [21 USC 321(g)(1)(B)]. Because your product is not generally recognized as safe and effective when used as labeled, it is also a new drug as defined in section 201(p) of the Act [21 USC 321(p)]. Under section 505 of the Act [21 USC 355 (a)], a new drug may not be legally marketed in the United States without an approved New Drug Application (NDA). This drug is also misbranded within the meaning of section 502(a) of the Act [21 USC 352(a)] because their labeling is false and misleading in that it suggests that this drug is effective for the prevention and treatment of avian flu and other forms of influenza when, in fact, these claims are not supported by competent and reliable scientific evidence.
This letter an all-inclusive review of your website and the products that your form markets. It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations.
You must immediately correct these violations. If you do not immediately correct them, you may be subject to enforcement action without notice. The Act provides for seizure of illegal products and for injunctions against the manufacturers and distributors of illegal products [21 USC 332 and 334]. Individuals and businesses that violate the Act may also be subject to criminal prosecution.
Please advise this office, in writing and within fifteen (15) working days of the receipt of this letter, as to the specific steps you haven taken to correct the violations noted above and to ensure that similar violations do not occur. If corrective actions cannot be completed within fifteen working days, state the reason for the delay and the time within which the corrections will be completed.
Your reply should be addressed to Compliance Officer Andrew Ciaocia at the above address.
Douglas I. Ellsworth
This page was posted on March 28, 2006.